* current hospitalization * participation in any other covid-19 trial * individuals that are taking antiviral medications * baseline lab/drug screen shows consumption of a schedule 1 narcotic * prior diagnosis of cancer and currently undergoing radiation, chemotherapy, or immunotherapy; excluding basal cell skin carcinoma * participants who have been diagnosed as hiv positive or taking anti-hiv therapy * female participants who are pregnant or breastfeeding, lactating, or planning a pregnancy during the trial. * female subjects who is/are breastfeeding or plans to breastfeed * medical disease or conditions such as high-risk comorbidities such as: diabetes, chronic obstructive pulmonary disease (copd) or emphysema, history of heart attack or stroke, history of coronary bypass surgery or coronary angioplasty or stent, history of hospitalization for heart failure, etc. * demonstrated inability to comply, tell the truth (as defined by pi, study investigator on subjects health condition) with the study procedures * history of hypersensitive or severe allergic reactions * anticipated need for immunosuppressive treatment within the next 6 months * received immunoglobulins and or any blood or blood products within the 4 months of being enrolled in this investigation * blood dyscrasias or significant disorder of coagulation. * severe liver disease including chronic liver disease, fatty liver, cirrhosis or awaiting transplant. * history of alcohol abuse or other recreational drug abuse of schedule 1 narcotics within 6 months of being enrolled in the study. * subjects diagnosed with: * kidney disease (ckd) \| end-stage renal disease (esrd) or dialysis. * a history of calcium oxalate kidney stones * mineral bone disorders.

* current hospitalization * participation in any other covid-19 trial * individuals that are taking antiviral medications * baseline lab/drug screen shows consumption of a schedule 1 narcotic * prior diagnosis of cancer and currently undergoing radiation, chemotherapy, or immunotherapy; excluding basal cell skin carcinoma * participants who have been diagnosed as hiv positive or taking anti-hiv therapy * female participants who are pregnant or breastfeeding, lactating, or planning a pregnancy during the trial. * female subjects who is/are breastfeeding or plans to breastfeed * medical disease or conditions such as high-risk comorbidities such as: diabetes, chronic obstructive pulmonary disease (copd) or emphysema, history of heart attack or stroke, history of coronary bypass surgery or coronary angioplasty or stent, history of hospitalization for heart failure, etc. * demonstrated inability to comply, tell the truth (as defined by pi, study investigator on subjects health condition) with the study procedures * history of hypersensitive or severe allergic reactions * anticipated need for immunosuppressive treatment within the next 6 months * received immunoglobulins and or any blood or blood products within the 4 months of being enrolled in this investigation * blood dyscrasias or significant disorder of coagulation. * severe liver disease including chronic liver disease, fatty liver, cirrhosis or awaiting transplant. * history of alcohol abuse or other recreational drug abuse of schedule 1 narcotics within 6 months of being enrolled in the study. * subjects diagnosed with: * kidney disease (ckd) \| end-stage renal disease (esrd) or dialysis. * a history of calcium oxalate kidney stones * mineral bone disorders.

- current hospitalization - participation in any other covid-19 trial - individuals that are taking antiviral medications - baseline lab/drug screen shows consumption of a schedule 1 narcotic - prior diagnosis of cancer and currently undergoing radiation, chemotherapy, or immunotherapy; excluding basal cell skin carcinoma - participants who have been diagnosed as hiv positive or taking anti-hiv therapy - female participants who are pregnant or breastfeeding, lactating, or planning a pregnancy during the trial. - female subjects who is/are breastfeeding or plans to breastfeed - medical disease or conditions such as high-risk comorbidities such as: diabetes, chronic obstructive pulmonary disease (copd) or emphysema, history of heart attack or stroke, history of coronary bypass surgery or coronary angioplasty or stent, history of hospitalization for heart failure, etc. - demonstrated inability to comply, tell the truth (as defined by pi, study investigator on subjects health condition) with the study procedures - history of hypersensitive or severe allergic reactions - anticipated need for immunosuppressive treatment within the next 6 months - received immunoglobulins and or any blood or blood products within the 4 months of being enrolled in this investigation - blood dyscrasias or significant disorder of coagulation. - severe liver disease including chronic liver disease, fatty liver, cirrhosis or awaiting transplant. - history of alcohol abuse or other recreational drug abuse of schedule 1 narcotics within 6 months of being enrolled in the study. - subjects diagnosed with: - kidney disease (ckd) | end-stage renal disease (esrd) or dialysis. - a history of calcium oxalate kidney stones - mineral bone disorders.

- current hospitalization - participation in any other covid-19 trial - individuals that are taking antiviral medications - baseline lab/drug screen shows consumption of a schedule 1 narcotic - prior diagnosis of cancer and currently undergoing radiation, chemotherapy, or immunotherapy; excluding basal cell skin carcinoma - participants who have been diagnosed as hiv positive or taking anti-hiv therapy - female participants who are pregnant or breastfeeding, lactating, or planning a pregnancy during the trial. - female subjects who is/are breastfeeding or plans to breastfeed - medical disease or conditions such as high-risk comorbidities such as: diabetes, chronic obstructive pulmonary disease (copd) or emphysema, history of heart attack or stroke, history of coronary bypass surgery or coronary angioplasty or stent, history of hospitalization for heart failure, etc. - demonstrated inability to comply, tell the truth (as defined by pi, study investigator on subjects health condition) with the study procedures - history of hypersensitive or severe allergic reactions - anticipated need for immunosuppressive treatment within the next 6 months - received immunoglobulins and or any blood or blood products within the 4 months of being enrolled in this investigation - blood dyscrasias or significant disorder of coagulation. - severe liver disease including chronic liver disease, fatty liver, cirrhosis or awaiting transplant. - history of alcohol abuse or other recreational drug abuse of schedule 1 narcotics within 6 months of being enrolled in the study. - subjects diagnosed with: - kidney disease (ckd) | end-stage renal disease (esrd) or dialysis. - a history of calcium oxalate kidney stones - mineral bone disorders.